Core Insights - Vaxart's oral bivalent norovirus vaccine candidate has shown safety and immunogenicity in a Phase 1 trial, leading to significant increases in norovirus-specific antibodies in both serum and breast milk of vaccinated postpartum women [1][2][3] Group 1: Vaccine Efficacy and Safety - The vaccine was well-tolerated with mild to moderate adverse events similar between vaccine and placebo groups, with no adverse events beyond grade 2 reported [4] - Serum norovirus-specific IgA increased by an average of 5.6-fold for GI.1 and 4.7-fold for GII.4 in the high-dose group, while breast milk IgA rose by 4.0-fold for GI.1 and 6.0-fold for GII.4 [4][5] - Elevated levels of specific IgA in breast milk were maintained through day 180, indicating sustained immune response [5] Group 2: Passive Immunity Transfer - The study demonstrated a positive correlation between breast milk IgA levels and norovirus-specific IgA in the stool of breastfed infants, suggesting effective passive transfer of immunity [1][2][5] - This passive immunity could protect infants under five years old, who are particularly vulnerable to severe norovirus infections [2] Group 3: Trial Details and Funding - The Phase 1 trial involved 76 healthy lactating women aged 18-43, randomized into high-dose, medium-dose, and placebo groups [3][4] - The study was partially funded by the Bill & Melinda Gates Foundation, highlighting its significance in addressing global health challenges [3] Group 4: Future Developments - Vaxart plans to initiate the next clinical trial for its norovirus oral vaccine candidate in 2026, pending partnership or additional funding [6]